Oral Alzheimer Drug Activates TREM2 in Human Brain, Moves to Phase 2 Trial
· techtimes.com · popularity 20/100 · 0 similar stories today · Brain & Neuroscience (Discovery & Research)
Read the original at techtimes.com →
Summary
Oral Alzheimer drug SAR448851 has confirmed TREM2 target engagement in living human brains, making it the first small-molecule TREM2 agonist to complete Phase 1 and advance to the 160-patient TREMHANCE Phase 2 trial. Sanofi's oral pill crosses the blood-brain barrier unaided and cut amyloid plaque by 40% in mice.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 3.